Immutep completes recruitment of initial NSCLC cohort
Filed with ASX · · 2 pages · English
Earlier from Immutep
- First patient dosed in INSIGHT-004
- Immutep granted European patent for eftilagimod alpha
- More mature positive data for TACTI-mel trial presented
- Immutep granted US patent for IMP321
- IMP761 results presented at ECCO conference
Later from Immutep
- Immutep granted Australian patent for eftilagimod alpha
- Immutep completes recruitment of AIPAC trial in MBC
- Immutep Entitlement Offer Booklet
- Entitlement Offer Results & Shortfall Notification
- Appendix 4E & 2019 Full Year Statutory Accounts
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep